These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30139291)

  • 1. A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
    Calnan MW; Crawford AN
    J Pharm Pract; 2020 Apr; 33(2):231-235. PubMed ID: 30139291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Cangrelor as Bridging Therapy Post PCI.
    Khan AA; Murtaza G; Khalid M; Finniss M; Helton T
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(3):227-231. PubMed ID: 32108005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of P2Y
    Spinthakis N; Farag M; Gue YX; Srinivasan M; Wellsted DM; Gorog DA
    Thromb Res; 2019 Jan; 173():102-108. PubMed ID: 30500673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and Reasons of Dual Antiplatelet Therapy Discontinuation and Switching of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome Treated with Stent Implantation.
    Fuertes Ferre G; Caballero Jambrina I; Ruiz Aranjuelo A; Jimeno Sánchez J; Galache Osuna JG; Andrés Esteban EM; Casasnovas Lenguas JA; Diarte de Miguel JA
    Cardiology; 2019; 142(4):203-207. PubMed ID: 31266007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cangrelor Bridge Therapy for Gastroduodenal Biopsy.
    Cahoon WD; Oswalt AK; Francis KE; Magee LC; Lowe DK
    J Pharm Pract; 2017 Apr; 30(2):270-273. PubMed ID: 27000137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Cangrelor as a Bridge to Left Ventricular Assist Device Implantation in a Patient with a Recent Drug-Eluting Stent Who Developed Acute Tirofiban-Related Thrombocytopenia.
    Kabadi RA; Danelich IM; Entwistle JW; Marhefka GD; Reeves G; Boyle AJ; Qureshi AM
    Pharmacotherapy; 2019 Apr; 39(4):521-525. PubMed ID: 30644585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cangrelor: a review on pharmacology and clinical trial development.
    Franchi F; Rollini F; Muñiz-Lozano A; Cho JR; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1279-91. PubMed ID: 24138516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative management of dual anti-platelet therapy.
    Webster TD; Vaishnava P; Eagle KA
    Hosp Pract (1995); 2016 Dec; 44(5):237-241. PubMed ID: 27846735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
    Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
    Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cangrelor in patients undergoing cardiac surgery: the BRIDGE study.
    Voeltz MD; Manoukian SV
    Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):811-6. PubMed ID: 23895024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
    Huber K; Bates ER; Valgimigli M; Wallentin L; Kristensen SD; Anderson JL; Lopez Sendon JL; Tubaro M; Granger CB; Bode C; Ohman EM; Steg PG
    Am Heart J; 2014 Nov; 168(5):611-21. PubMed ID: 25440788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
    Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
    Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cangrelor for treatment during percutaneous coronary intervention.
    Oestreich JH; Dobesh PP
    Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Intravenous Cangrelor as Antiplatelet Bridge Therapy in a Patient Undergoing Esophageal Dilation Procedure.
    Choxi R; Pillai A; Ahmed S; Jovin IS
    Cardiovasc Revasc Med; 2020 Nov; 21(11S):94-95. PubMed ID: 31932170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of data on cangrelor.
    Qamar A; Bhatt DL
    Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.